// App-Quantinova.ai

998 : A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate, Sodium Salt) in Sickle Cell Disease

Researchers

Presenter

  • Marvin Reid

Principal Investigators

  • Ali T Taher

  • Patrick BWalter

  • Punam Malik

  • Ofelia A. Alvarez

  • Richard Ward

  • J Michael White

  • Elsa Johnson

  • Richard G. Ghalie

  • Adlette Inati

  • Miguel R. Abboud

  • Amal El-Beshlawy

  • George R. Buchanan

  • Hedy Smith

  • Kenneth I. Ataga

  • Nebu Koshy

  • Lynne D Neumayr

Medical Centers

  • Chronic Care Center, Beirut, Lebanon

  • Sickle Cell Unit, University of the West Indies at Mona, Kingston, Jamaica, Kingston, Jamaica

  • Children's Cancer Center of Lebanon, Beirut, Lebanon

  • Cairo University, Cairo, Egypt

  • Department of Pediatric Hematology and Oncology, Rafik Hariri University Hospital, Beirut, Lebanon

  • GRU Cancer Center, Georgia Regents University, Augusta, GA

  • Hematology/Oncology, Children's Hospital & Division of Medical Oncology and Hematology, Dept of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada

Locations

  • Canada

  • Jamaica

  • Lebanon

  • United States

  • Egypt

Companies

  • HemaQuest Pharmaceut

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Sickle cell anemia

  • Pancreatitis

Biomarkers

  • Aspartate aminotransferase

  • Stearoyl-CoA desaturase

Drug/Treatment

  • Hydroxyurea

  • Hydroxycarbamide

  • HQK1001

Outcome

  • N/A

Study Design

  • open label

  • pharmacodynamics

Phase

  • NA

Study Id's

  • NCT01322269

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved